Capricor Therapeutics, Inc. (CAPR)
Largest Insider Buys in Sector
CAPR Stock Price History Chart
CAPR Stock Performance
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company …
Insider Activity of Capricor Therapeutics, Inc.
Over the last 12 months, insiders at Capricor Therapeutics, Inc. have bought $15M and sold $0 worth of Capricor Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Capricor Therapeutics, Inc. have bought $5.02M and sold $474.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Nippon Shinyaku Co Ltd (10 percent owner) — $15M.
The last purchase of 2,798,507 shares for transaction amount of $15M was made by Nippon Shinyaku Co Ltd (10 percent owner) on 2024‑09‑20.
List of Insider Buy and Sell Transactions, Capricor Therapeutics, Inc.
| 2024-09-20 | 10 percent owner | 2.8M 9.1284% | $5.36 | $15M | +258.42% | |||
| 2023-10-12 | director | 410 0.0015% | $2.75 | $1,128 | +63.96% | |||
| 2023-10-10 | director | 10,000 0.0395% | $2.83 | $28,300 | +62.63% | |||
| 2023-10-09 | director | 5,083 0.02% | $2.82 | $14,334 | +66.55% | |||
| 2023-10-06 | director | 5,000 0.019% | $2.84 | $14,200 | +58.10% | |||
| 2023-10-04 | director | 2,500 0.0095% | $2.90 | $7,250 | +61.27% | |||
| 2023-04-17 | Sale | 14,772 – | $64,258.00 | $949.22M | +3.50% | |||
| 2023-03-28 | Sale | 3,000 0.0118% | $4.06 | $12,180 | +6.59% | |||
| 2022-06-29 | Sale | 28,215 0.1163% | $3.77 | $106,371 | +19.68% | |||
| 2022-06-29 | CHIEF BUSINESS OFFICER | 1,500 0.0062% | $3.76 | $5,643 | +19.68% | |||
| 2022-06-27 | Sale | 17,775 0.0736% | $4.44 | $78,921 | +1.59% | |||
| 2017-05-09 | 10 percent owner | 2.29M 11.0606% | $3.10 | $7.1M | -46.21% | |||
| 2017-05-09 | director | 20,000 0.0966% | $3.10 | $62,000 | -46.21% | |||
| 2017-05-09 | director | 50,000 0.2415% | $3.10 | $155,000 | -46.21% | |||
| 2016-09-21 | 10 percent owner | 625,000 3.0673% | $3.20 | $2M | -26.89% | |||
| 2016-03-16 | 10 percent owner | 833,332 4.8375% | $2.40 | $2M | +29.40% | |||
| 2016-03-16 | director | 182,738 1.0608% | $2.40 | $438,571 | +29.40% | |||
| 2016-03-16 | 10 percent owner | 833,332 4.8375% | $2.40 | $2M | +29.40% | |||
| 2016-03-16 | Chief Executive Officer | 30,456 0.1768% | $2.40 | $73,094 | +29.40% | |||
| 2016-03-16 | director | 200,000 1.161% | $2.40 | $480,000 | +29.40% |
Insider Historical Profitability
| Nippon Shinyaku Co Ltd | 10 percent owner | 7090351 15.5935% | $14.01 | 1 | 0 | |
| CEDARS SINAI MEDICAL CENTER | 10 percent owner | 4049959 8.9069% | $14.01 | 4 | 0 | +25.52% |
| Marban Eduardo | 10 percent owner | 3173354 6.979% | $14.01 | 2 | 0 | <0.0001% |
| KASH PETER M | director | 1596208 3.5105% | $14.01 | 3 | 0 | |
| TANEN DAVID M | director | 1520705 3.3444% | $14.01 | 4 | 0 |
Institutional Investor Ownership
| The Vanguard Group | $9.27M | 4.29 | 1.37M | +17.2% | +$1.36M | <0.0001 | |
| BlackRock | $2.59M | 1.2 | 381,735 | +6.13% | +$149,801.00 | <0.0001 | |
| Geode Capital Management | $2.23M | 1.03 | 328,477 | +3.88% | +$83,391.31 | <0.0001 | |
| Susquehanna International Group | $2.15M | 0.99 | 316,260 | +112.09% | +$1.13M | <0.01 | |
| Millennium Management LLC | $1.99M | 0.92 | 293,041 | +1,292.91% | +$1.85M | <0.01 |